CAMP
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- CAMP4 Therapeutics received UK authorization to begin a Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorderSep 10, 2026
- CAMP4 Therapeutics receives Australian clearance to begin first-in-human trial of CMP-002Jul 27, 2026
- CAMP4 Therapeutics will present preclinical data showing CMP-002 improved seizure threshold and severity in SYNGAP1-related disorder modelsMay 14, 2026
- CAMP4 Therapeutics released a pioneering preprint study on regulatory RNA profiling and gene upregulationApr 28, 2026